Quick Answer
Vanda Pharmaceuticals Inc. reported Total Assets of $488.95 million for the year ending 2025.
- Vanda Pharmaceuticals Inc. showed a decrease of -25.5% in Total Assets from 2024 to 2025.
- This data is from Vanda Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $203.44 million | Q3 2011: $195.74 million | Q1 2012: $172.60 million | Q2 2012: $160.84 million | Q3 2012: $149.81 million | Q1 2013: $125.14 million | Q2 2013: $116.95 million | Q3 2013: $155.09 million | Q1 2014: $120.98 million | Q2 2014: $86.17 million | Q3 2014: $79.18 million | Q1 2015: $213.64 million | Q2 2015: $223.69 million | Q3 2015: $220.54 million | Q1 2016: $206.74 million | Q2 2016: $202.04 million | Q3 2016: $208.44 million | Q1 2017: $204.72 million | Q2 2017: $210.67 million | Q3 2017: $205.71 million | Q1 2018: $317.32 million | Q2 2018: $302.93 million | Q3 2018: $311.94 million | Q1 2019: $351.17 million | Q2 2019: $372.48 million | Q3 2019: $474.45 million | Q1 2020: $488.53 million | Q2 2020: $506.63 million | Q3 2020: $515.91 million | Q1 2021: $543.19 million | Q2 2021: $567.65 million | Q3 2021: $579.77 million | Q1 2022: $603.56 million | Q2 2022: $609.10 million | Q3 2022: $621.79 million | Q1 2023: $644.53 million | Q2 2023: $641.68 million | Q3 2023: $641.61 million | Q1 2024: $652.68 million | Q2 2024: $651.37 million | Q3 2024: $645.12 million | Q1 2025: $631.94 million | Q2 2025: $624.75 million | Q3 2025: $601.14 million.
- Over the full 16 years of available data (2010 to 2025), Vanda Pharmaceuticals Inc.'s Total Assets has grown by 129.4%.
- Historical annual values: Fiscal year 2025: $488.95 million | Fiscal year 2024: $656.20 million | Fiscal year 2023: $648.44 million | Fiscal year 2022: $634.25 million | Fiscal year 2021: $593.79 million | Fiscal year 2020: $533.46 million | Fiscal year 2019: $483.75 million | Fiscal year 2018: $332.13 million | Fiscal year 2017: $205.43 million | Fiscal year 2016: $210.37 million | Fiscal year 2015: $213.05 million | Fiscal year 2014: $171.70 million | Fiscal year 2013: $143.35 million | Fiscal year 2012: $135.45 million | Fiscal year 2011: $182.62 million | Fiscal year 2010: $213.10 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: